{"playerId":1238,"percentChange":9.5,"averageDraftPosition":98.1,"percentOwned":98.7,"playerRaterSEASON":1.8,"playerRater7DAY":3.5,"mostRecentNews":{"news":"Cabrera (hamstring) started Wednesday's win over San Francisco, going 1-for-3 with a double and a pair of runs scored.","spin":"Cabrera underwent an MRI on both of his hamstrings prior to the game, but no serious injury was revealed and he won't be forced to miss any time. He continues to swing a hot bat, hitting .351 with a home run and eight RBI in the month of May.","date":"Wed May 15"},"fullName":"Melky Cabrera","seasonOutlook":{"outlook":"The Blue Jays have learned a valuable lesson that fantasy owners should, too: Without specific evidence that players are due a steep statistical decline following a suspension for PEDs, we shouldn't be so fast to assume it'll happen. The team took a bit of a leap of faith by signing Cabrera to a two-year, $16 million contract during the winter, despite the fact that the 28-year-old outfielder didn't play in a single game after Aug. 14 last season, serving a 50-game suspension for testing positive for elevated testosterone levels then being held out of the Giants' World Series championship run as a team decision. The Blue Jays, assuming that Cabrera shouldn't slip far from the .360-on-base, double-double power/speed player we saw the past two seasons combined, are banking on him being a handy asset in the top third of their lineup, where his runs scored total should benefit from the team's winter additions. Unfortunately, in the absence of evidence, we have no idea whether Cabrera's performance will return to his 2006-10 levels, when he wasn't much of a mixed-league factor. It could happen. Much more likely -- primarily because of role, ballpark and supporting cast -- he'll be a closer to the ballplayer of 2011-12, and that's the way he should be valued.","seasonId":2013,"date":"Wed Feb 20"},"playerRater30DAY":1.5,"playerRater15DAY":3.3,"positionRank":59}